Patents Assigned to Chr. Hansen HMO GmbH
  • Patent number: 11981947
    Abstract: The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: May 14, 2024
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Publication number: 20240110213
    Abstract: Disclosed are genetically engineered microbial cells for the production of an oligosaccharide of interest, wherein said microbial cells possess a variant of the E. coli lactose permease LacY which exhibits a reduced transport activity for lactose, and methods for producing an oligosaccharide by using said genetically engineered microbial cells.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 4, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Henning Frerigmann, Christian Trötschel, Dirk Wartenberg, Stefan Jennewein
  • Patent number: 11920173
    Abstract: Disclosed are non-naturally-occurring microorganisms for the production of N-acetylneuraminic acid, a method for the production of N-acetylneuraminic acid by fermentation of the non-naturally-occurring microorganisms, and nutritional compositions containing N-acetylneuraminic acid which has been produced by fermentation of the non-naturally-occurring microorganisms.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 5, 2024
    Assignee: Chr Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Patent number: 11912735
    Abstract: Disclosed is a method for purifying sialylated oligosaccharides from a fermentation broth, cell-lysate or biocatalytic reaction mixture for obtaining high amounts of desired sialylated oligosaccharides in high purity. The method is particular suitable for the large-scale economic purification of sialylated human milk oligosaccharides (such as 3?-sialyllactose, 6?-sialyllactose or sialylated lacto-N-tetraose derivatives) from microbial fermentation, using recombinant bacterial cells or yeast cells. The obtained material is of high purity and can be used for food or medical application such like medical nutrition products, infant formula, dietary supplements, general nutrition products (e.g. dairy drinks).
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: February 27, 2024
    Assignee: Chr Hansen HMO GmbH
    Inventors: Stefan Jennewein, Markus Helfrich, Benedikt Engels
  • Publication number: 20240052324
    Abstract: Disclosed are enzymes, compositions, genetically engineered cells and methods for the fermentative production of 6?-sialyllactose.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 15, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Patent number: 11898185
    Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 13, 2024
    Assignee: Chr Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Publication number: 20240026403
    Abstract: The present invention concerns an efficient way to isolate L-fucose from a fermentation broth. The L-fucose contained in the fermentation broth is produced by microbial fermentation (bacterial or yeasts). The inventive process comprises a step of removing biomass from the fermentation broth, a step of subjecting the resulting solution to at least one of a cationic ion exchanger treatment and an anionic ion exchanger treatment and a step of removing salts after the ion exchanger treatment. The process can provide L-fucose in powder form, in granulated form as well as in form of L-fucose crystals.
    Type: Application
    Filed: June 29, 2023
    Publication date: January 25, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Markus Helfrich, Stefan Jennewein
  • Publication number: 20230399669
    Abstract: Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-?1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 14, 2023
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Patent number: 11834691
    Abstract: The present invention describes an efficient way to isolate a sialic acid from a fermentation broth. The sialic acid contained in the fermentation broth is produced by bacterial fermentation. The inventive process comprises a step of removing biomass from the fermentation broth, a step of subjecting the resulting solution to at least one of a cationic ion exchanger treatment and an anionic ion exchanger treatment and a step of removing salts after the ion exchanger treatment. The process can provide the sialic acid in spray-dried form as well as in form of sialic acid crystals.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: December 5, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Markus Helfrich
  • Publication number: 20230304052
    Abstract: Disclosed are genetically-engineered gram-negative bacterial cells for the production of an oligosaccharide of interest, wherein the bacterial cell possesses a saccharide transporter and/or a porin being expressed from a recombinant gene or a deregulated endogenous gene, thereby facilitating the translocation of the oligosaccharide of interest from the cell's cytoplasm into the cell's environment. Also disclosed are methods for producing an oligosaccharide of interest which used said genetically-engineered gram-negative bacterial cells.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 28, 2023
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Markus Englert, Stefan Jennewein, Henning Frerigmann, Katja Parschat, Christian Trötschel
  • Publication number: 20230271992
    Abstract: Provided is a method for the purification of lacto-N-neotetraose from other carbohydrates, characterized in that the method comprises the steps of subjecting an aqueous solution containing lacto-N-neotetraose to two membrane filtration steps using different membranes or of subjecting an aqueous solution containing lacto-N-neotetraose to a membrane filtration step and a continuous chromatography.
    Type: Application
    Filed: May 10, 2023
    Publication date: August 31, 2023
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Markus Helfrich
  • Patent number: 11732282
    Abstract: The present invention concerns an efficient way to isolate L-fucose from a fermentation broth. The L-fucose contained in the fermentation broth is produced by microbial fermentation (bacterial or yeasts). The inventive process comprises a step of removing biomass from the fermentation broth, a step of subjecting the resulting solution to at least one of a cationic ion exchanger treatment and an anionic ion exchanger treatment and a step of removing salts after the ion exchanger treatment. The process can provide L-fucose in powder form, in granulated form as well as in form of L-fucose crystals.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 22, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Markus Helfrich, Stefan Jennewein
  • Patent number: 11713475
    Abstract: Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-?1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: August 1, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Patent number: 11685758
    Abstract: Provided is a method for the purification of lacto-N-neotetraose from other carbohydrates, characterized in that the method comprises the steps of subjecting an aqueous solution containing lacto-N-neotetraose to two membrane filtration steps using different membranes or of subjecting an aqueous solution containing lacto-N-neotetraose to a membrane filtration step and a continuous chromatography.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: June 27, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Markus Helfrich
  • Patent number: 11661435
    Abstract: The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: May 30, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Publication number: 20230148644
    Abstract: Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of LNT and/or LNnT, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 18, 2023
    Applicant: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Patent number: 11597740
    Abstract: The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 7, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Patent number: 11582994
    Abstract: Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3-fucosyllactose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: February 21, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Publication number: 20220403433
    Abstract: The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 22, 2022
    Applicant: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Publication number: 20220395519
    Abstract: The present invention relates to a method for drying human milk oligosaccharides (HMOs). More specifically, the present invention is related to a method of roller drying or drum drying of human milk oligosaccharides in a simple and economical way.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 15, 2022
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Mischa Baier, Tobias Seitz, Markus Helfrich